Juq-097

| Physiological role | Relevance to disease | |--------------------|----------------------| | (rodent models). | Alcohol, opioids, and nicotine relapse are driven by NOP activation. | | Regulates dopamine release in the mesolimbic pathway . | Dampening NOP signaling restores normal reward processing, reducing craving. | | Interacts with the HPA‑axis (corticotropin‑releasing factor). | Chronic stress fuels depressive and anxiety phenotypes. | | Controls pain perception and analgesic tolerance . | Potential to counter opioid‑induced hyperalgesia. |

JUQ-097 is more than just a research compound – it represents a key to unlocking new scientific knowledge. By providing researchers with a powerful tool to study complex biological processes, JUQ-097 has the potential to drive significant advances in various fields of study. Whether it is used to study the mechanisms of disease or to develop novel therapies, JUQ-097 is poised to play a major role in shaping the future of scientific research. JUQ-097

| Phase | Design | Enrollment | Status | Key Outcomes | |-------|--------|------------|--------|--------------| | (US/Europe) | Single‑ascending dose (SAD) & multiple‑ascending dose (MAD) in healthy volunteers. | 96 | Completed 2023 | • Linear PK, t½ ≈ 9 h. • No serious AEs. • Max tolerated dose = 120 mg qd. | | Phase Ib (AUD) | Randomized, double‑blind, 2‑week lead‑in, 4‑week treatment. 30 mg vs. placebo. | 48 (moderate‑severity AUD) | Completed 2024 | • Primary: % heavy‑drinking days ↓ 27 % vs. 5 % placebo (p = 0.004). • Secondary: Craving VAS ↓ 34 % (p = 0.001). | | Phase IIa (AUD + MDD) | 12‑week, 2‑arm (30 mg vs. 60 mg) with standard psychosocial counseling. | 210 (AUD + comorbid MDD) | Ongoing – Interim analysis (Week 8) | • Trend toward greater abstinence rates (60 % vs. 45 % placebo). • PHQ‑9 reduction of 5 points vs. 2 points (p = 0.02). | | Phase IIb/III (planned) | Global, multicenter, 24‑week, 3 arms (30 mg, 60 mg, placebo). Primary endpoint: % days abstinent; key secondary: relapse‑free survival, depressive symptom remission. | ~1,200 (target) | Recruitment slated for Q4 2026 | — | | Physiological role | Relevance to disease |